Autologous Anti-DLL3 CAR-T Cells LB2102

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-DLL3 CAR-T cells LB2102 recognize and induce selective toxicity in DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.

**Synonyms:** - Autologous Anti-DLL3 CAR T Cells LB2102 - Autologous DLL3-directed CAR T-cells LB2102 - LB 2102 - LB-2102 - LB2102